Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer (CTC-MBC)
Women with metastatic breast cancer, receiving first line treatment of any kind (chemotherapy, endocrine treatment or treatment with antibodies) will be included in this trial. In connection to treatment, blood samples for determination and enumeration of circulating tumour cells will be collected at different time points. Serum and plasma will be collected and stored for future analysis of RNA and DNA.
Metastatic Breast Cancer
|Study Design:||Time Perspective: Prospective|
|Official Title:||Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer|
- To determine whether numbers of circulating tumour cells in peripheral blood can give information of prognosis, and to evaluate if the numbers of circulating tumour cells can give information of the efficacy of given treatment [ Time Frame: Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6. ] [ Designated as safety issue: No ]
|Study Start Date:||March 2011|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
|Contact: Lisa Ryden, MD, PhD||+46 46 17 10 email@example.com|
|Contact: Anette Ahlin Gullers, RN||+46 46 17 76 firstname.lastname@example.org|
|Lund University Hospital||Recruiting|
|Lund, Sweden, 221 85|
|Contact: Anna-Maria Larsson, MD +46 46 17 10 00 email@example.com|
|Contact: Anette Ahlin Gullers, RN +46 46 17 76 34 firstname.lastname@example.org|
|Principal Investigator: Lisa Rydén, MD, PhD|